Skip to content
OpenCapital
Get started

MiMedx Group MDXG EPS (Diluted)

EPS (Diluted) at other companies

IAR
Integra LifeSciencesIART
-$0.06+81.8%
Solventum logo
SolventumSOLV
$0.07-91.0%
Vericel logo
VericelVCEL
-$0.12+47.8%
Enovis logo
EnovisENOV
-$0.15+84.7%
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
-$0.08+38.5%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$1.22+34.1%

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's EPS (diluted)?
MiMedx Group (MDXG) reported EPS (diluted) of -$0.07 in Q1 2026.
How has MiMedx Group's EPS (diluted) changed year-over-year?
MiMedx Group's EPS (diluted) decreased by 240.0% year-over-year, from $0.05 to -$0.07.
What is the long-term trend for MiMedx Group's EPS (diluted)?
Over 4 years (2021 to 2025), MiMedx Group's EPS (diluted) has grown at a 18.9% compound annual growth rate (CAGR), from -$0.16 to $0.32.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.